BCM
NERV icon

BlueCrest Capital Management’s Minerva Neurosciences NERV Stock Holding History

BlueCrest Capital Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,347
Closed -$95K – 1009
2017
Q2 		$95K Buy
+1,347
New +$87.2K ﹤0.01% 823

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlueCrest Capital Management's NERV Position: Q3 2017 in Review

BlueCrest Capital Management sold out of Minerva Neurosciences (NERV) in Q3 2017, closing a stake of 1,347 shares — an estimated $95K sold.

BlueCrest Capital Management first reported a position in NERV in Q2 2017 and held it in 1 quarter. The position peaked at $95K in Q2 2017. 70 funds tracked by Wall St. Rank hold NERV as of Q3 2017.

  • BlueCrest Capital Management reported no remaining Minerva Neurosciences position as of Q3 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 1,347 Minerva Neurosciences shares in Q3 2017, an estimated $95K.
  • BlueCrest Capital Management first reported a position in Minerva Neurosciences in Q2 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's Minerva Neurosciences position peaked at $95K in Q2 2017.
  • 70 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q3 2017.

Based on BlueCrest Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.